Oliver Sexton

Investment Director • UK Innovation & Science Seed Fund

Oliver joined UKI2S in 2014 to manage its life science and healthcare investments. He was the founding investor in Quethera (acquired by Astellas) and is on the board of various biotech companies including Gyreox and Ikarovec. He invests predominantly in biotech but the fund can also back agritech and clean tech companies.

Prior to joining UKI2S Oliver managed commercialisation of bioengineering and medical technologies at Imperial Innovations and worked at Ark Therapeutics where he managed BD and licensing. He has a background in strategy analysis and consultancy in London and New York including managing a team of buy-side analysts at Instinet. 

He has a BSc and MSc from Bristol University

Also speaking

Toby Proctor

Head of Manufacturing Science & Technology • Achilles Therapeutics

Ludwig Camusot

Chief Corporate Development Officer • Cell Matters

Sven Kili

Chief Executive Officer • Antion

Event Info


2022 Spotlight Roundtables

Take a look at the 2022 sample attendee list for Advanced Therapies Europe here.

Pub & Pints RSVP

Let us know you’re planning on attending.